MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 28, 2005; DOI: 10.1124/mol.105.015255


0026-895X/06/6902-539-546$20.00
Mol Pharmacol 69:539-546, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.015255v1
69/2/539    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Florio, T.
Right arrow Articles by Schettini, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Florio, T.
Right arrow Articles by Schettini, G.

Chemokine Stromal Cell-Derived Factor 1{alpha} Induces Proliferation and Growth Hormone Release in GH4C1 Rat Pituitary Adenoma Cell Line through Multiple Intracellular Signals

Tullio Florio, Silvia Casagrande, Fabrizio Diana, Adriana Bajetto, Carola Porcile, Gianluigi Zona, Stefano Thellung, Sara Arena, Alessandra Pattarozzi, Alessandro Corsaro, Renato Spaziante, Mauro Robello, and Gennaro Schettini

Section of Pharmacology, Department of Oncology Biology and Genetics (T.F., F.D., A.B., C.P., S.T., S.A., A.P., A.C., G.S.), Unit INFM, Department of Physics, (S.C., M.R.), and Division of Neurosurgery, Department of Neuroscience, Ophthalmology, and Genetics (G.Z., R.S.), University of Genova, Genova, Italy

We used GH4C1 cells as a model to study the effects of the chemokine stromal cell-derived factor 1 (SDF1) in pituitary functions. In these cells, SDF1{alpha} induced proliferation and growth hormone secretion, suggesting a possible regulatory role for this chemokine at pituitary level. We evaluated the intracellular signaling involved in these effects: SDF1{alpha} increased cytosolic [Ca2+] and activated Pyk2, extracellular signal-regulated kinases 1 and 2 (ERK1/2), and large-conductance Ca2+-activated K+ channels (BKCa) channels. To correlate these intracellular effectors with the proliferative and secretory effects, we inhibited their activity using BAPTA-AM (Ca2+ chelator), 2'-amino-3'-methoxyflavone (PD98059; a mitogen-activated protein kinase kinase inhibitor), salicylate (Pyk2 inhibitor), and tetraethyl ammonium (K+ channel blocker). All of these compounds reverted SDF1{alpha}-induced proliferation, suggesting the involvement of multiple intracellular pathways. Conversely, only BAPTA-AM reverted growth hormone secretion. To identify a possible cross-talk and a molecular ordering among these pathways, we tested these antagonists on SDF1{alpha}-dependent activation of ERK1/2, Pyk2, and BKCa channels. From these experiments, we observed that the inhibition of [Ca2+]i increase or BKCa channel activity did not affect ERK1/2 activation by SDF1{alpha}; Pyk2 activation was purely Ca2+-dependent, not involving ERK1/2 or BKCa channels; and BKCa channel activity was antagonized by Pyk2 but not by ERK1/2 inhibitors. These data suggest that an SDF1{alpha}-dependent increase of [Ca2+]i activates Pyk2, which in turn regulates BKCa channel activity. Conversely, ERK1/2 activation is an independent phenomenon. In conclusion, we demonstrate that SDF1{alpha} causes both proliferation and growth hormone release from pituitary adenoma cells, suggesting that the activation of CXCR4 may represent a novel regulatory mechanism for growth hormone secretion and pituitary cell proliferation, which may contribute to pituitary adenoma development.


Received May 27, 2005; accepted October 28, 2005

Address correspondence to: Dr. Tullio Florio, Sezione Farmacologia, Dipartimento Oncologia, Biologia e Genetica, Università di Genova, Largo Rosanna Benzi 10, 16132 Genova, Italy. E-mail: tullio.florio{at}unige.it




This article has been cited by other articles:


Home page
J EndocrinolHome page
Y. Lee, J. M. Kim, and E. J. Lee
Functional expression of CXCR4 in somatotrophs: CXCL12 activates GH gene, GH production and secretion, and cellular proliferation
J. Endocrinol., November 1, 2008; 199(2): 191 - 199.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. Barbieri, A. Bajetto, R. Stumm, A. Pattarozzi, C. Porcile, G. Zona, A. Dorcaratto, J.-L. Ravetti, F. Minuto, R. Spaziante, et al.
Overexpression of Stromal Cell-Derived Factor 1 and Its Receptor CXCR4 Induces Autocrine/Paracrine Cell Proliferation in Human Pituitary Adenomas
Clin. Cancer Res., August 15, 2008; 14(16): 5022 - 5032.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. Pattarozzi, M. Gatti, F. Barbieri, R. Wurth, C. Porcile, G. Lunardi, A. Ratto, R. Favoni, A. Bajetto, A. Ferrari, et al.
17 -Estradiol Promotes Breast Cancer Cell Proliferation-Inducing Stromal Cell-Derived Factor-1-Mediated Epidermal Growth Factor Receptor Transactivation: Reversal by Gefitinib Pretreatment
Mol. Pharmacol., January 1, 2008; 73(1): 191 - 202.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
C. Callewaere, G. Banisadr, W. Rostene, and S. M. Parsadaniantz
Chemokines and chemokine receptors in the brain: implication in neuroendocrine regulation
J. Mol. Endocrinol., March 1, 2007; 38(3): 355 - 363.
[Abstract] [Full Text] [PDF]


Home page
J Mol EndocrinolHome page
F. Barbieri, A. Bajetto, C. Porcile, A. Pattarozzi, G. Schettini, and T. Florio
Role of stromal cell-derived factor 1 (SDF1/CXCL12) in regulating anterior pituitary function
J. Mol. Endocrinol., March 1, 2007; 38(3): 383 - 389.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics